Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases

Expert Opinion on Investigational Drugs

Volumn 9, Issue 9, 2000, Pages 2159-2165

  Scatena, R ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Angiogenesis; Cancer; Extracellular matrix; Matrix metalloproteinases; Metastasis; Tissue remodelling

Indexed keywords

CARBOPLATIN; HYDROXAMIC ACID DERIVATIVE; MATRIX METALLOPROTEINASE INHIBITOR; MITOXANTRONE; PACLITAXEL; PRINOMASTAT; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BONE PAIN; BREAST CANCER; CANCER INHIBITION; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOLOGY; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLIOMA; HUMAN; LUNG CANCER; LUNG SMALL CELL CANCER; MELANOMA; MYALGIA; NONHUMAN; OPHTHALMOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROSTATE CANCER; RIGIDITY; SIDE EFFECT;

EID: 0033864065     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.9.2159     Document Type: Article

References (17)

1. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials
2. Matrix metalloproteinases degradation of extracellular matrix: Biological consequences
3. Matrix metalloproteinases: Multifunctional contributors to tumor progression
4. Matrix metalloproteinase inhibitors
5. The next generation of MMP inhibitors. Design and synthesis
6. Matrix metalloproteinases: Biologic activity and clinical implications
7. Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases
8. AG3340, a novel matrix metalloproteinase (MMP) inhibitor, decreases growth and metastases of orthotopic human lung cancer in a nude rat preclinical model system
9. Marked inhibition of the proliferation of human adenocarcinoma colon tumors in vivo by orally administered AG3340, a novel matrix metalloproteinase (MMP) inhibitor
10. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor prinomastat
11. Marked antiangiogenic and antitumor efficacy of prinomastat in chemoresistant human non-small cell lung cancer tumors: Single agent and combination chemotherapy studies
12. Broad antitumor and antiangiogenic activities of prinomastat, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials
13. Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations
14. A novel approach to studying the efficacy of AG3340, a selective inhibitor of matrix metalloproteases
15. A Phase I trial of AG3340, a matrix metalloprotease (MMP) inhibitor, in patients having advanced cancer
16. Phase I Study of the matrix metalloprotease inhibitor AG3340 in combination with paclitaxel and carboplatin for the treatment of patients with advanced solid tumors
17. A Phase I pharmacokinetic evaluation of the matrix metalloprotease (MMP) inhibitor AG3340 in combination with mitoxantrone and prednisone in patients with advanced prostate cancer